Aeon Biopharma, INC 10-Q quarterly reports

AEON Biopharma, Inc. reported continued operating losses and a significant accumulated deficit in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, even after recent capital raises.

AEON Biopharma reported continued operating losses and a strategic pivot to a Botox biosimilar pathway, securing new financing while addressing going concern doubts and NYSE American listing compliance.

AEON Biopharma reported a strategic shift to a biosimilar pathway for ABP-450, raised $18.3M in a public offering, and faces a going concern warning despite improved cash position.

AEON Biopharma, Inc. filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the period ended March 31, 2025, solely to include a previously omitted exhibit related to an amendment to its Amended and Restated Bylaws.

AEON Biopharma reports a net income for Q1 2025, driven by fair value adjustments, while navigating strategic changes and substantial doubt about its ability to continue as a going concern.

AEON Biopharma's Q3 2024 results show a net loss, a strategic shift to a biosimilar pathway for ABP-450, and ongoing efforts to secure additional funding.

AEON Biopharma announced its Q2 2024 results, highlighted by a strategic shift to pursue a biosimilar regulatory pathway for its lead product candidate, ABP-450.

AEON Biopharma's Q1 2024 results show a significant net loss and operating expenses increase, coupled with a going concern warning following a failed clinical trial.

AEON Biopharma has amended its Q3 2023 quarterly report due to errors in valuation estimates, impacting reported losses and liabilities.